For patients with stage 2 or greater bladder cancer, care transitions linked with treatment delay
the ONA take:
According to a new study published in the Journal of Urology, researchers have found patients with stage 2 or higher urothelial carcinoma who underwent a care transition were more likely to experience a delay in treatment of 3 months or greater.
For the study, researchers sought to investigate whether changing hospitals between diagnosis and therapy for patients with muscle invasive bladder cancer would experience a delay in timely treatment. They identified 22,251 patients with stage 2 or greater urothelial carcinoma treated between 2003 and 2010 from the National Cancer Database.
Patients were considered to have underwent a care transition if they experienced a change in hospital between diagnosis of cancer and treatment with radical cystectomy or the initiation of neoadjuvant chemotherapy. Of all patients identified, 14.2% experienced a treatment delay of 3 months or more.
This proportion increased from 13.5% between 2003 and 2006 to 14.8% between 2007 and 2010 (P = 0.01). Of the patients who underwent a care transition, 19.4% experienced a treatment delay of 3 months or greater versus 10.7% who were diagnosed and treated at the same facility. The authors suggest that expediting care transitions at the time of hospital referral may improve the quality of care for patients with muscle invasive bladder cancer.
Patients with stage 2 or higher urothelial carcinoma who underwent care transition more likely to experience a delay in treatment.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|